I. Introduction
Beta thalassemia is a genetic disorder and one of the most common hemoglobinopathies. Mutations involving the beta globin gene in β Thalassemia cause disruption in red cell maturation leading to ineffective erythropoiesis and was associated with erythrocyte dysplasia and destruction. As chronic anaemia adversely affects the growth and development of the children, iron accumulation in the tissues due to destruction of the red blood cells, excessive blood transfusion create a negative impact on the organs functions 1 .One of the tissues affected by thalassemia major is eyes. Thalassemia patients are taking regular blood transfusion therapy which causes iron overload. Adverse ocular changes may occur as a result of the disease and includes visual defect, cataract, retinal pigment epithelial degeneration, retinal pigment epithelial mottling, retinal venous tortuosity, vitreoretinal haemorrhage, disc changes etc 2 .
II. Material And Methods
It was a cross sectional observational study. The study was carried out in the department of Paediatrics and the department of Ophthalmology Gandhi Medical College, Bhopal for duration of 10 months. 52 children diagnosed as beta Thalassemia major patients were enrolled in the study. All children enrolled have been receiving treatment in the form of packed red cell transfusion at a dose of 10 ml/kg body weight in order to maintain their haemoglobin concentration between 9 -11 gm/dl and iron chelating agents were started if the serum Ferritin level was above 1000 µg/dl. To compare the results 30 age matched controls with anaemia were recruited. An informed consent for participation was obtained. Patients with haemoglobin disorders other than beta thalassemia major ,congenital ocular abnormalities and ocular trauma were excluded.
All Thalassemia Major And Control Patients In This Study Were Subjected To The Following:
Full medical history including onset and duration of the disease, frequency of blood transfusions per month, Iron chelating agents dose, duration and compliance. Thorough physical examination performed Each patient underwent a complete eye examination Bhopal which includes visual acuity, slit lamp examination, fundoscopy. Uncorrected visual acuity was determined monocularly, at 6 meter using snellen's chart, illuminated with luminance of 100 cd/m2. Anterior segment examination was carried out with a (SI.No.SLPS-H1301321 Appasamy associate's-Chennai, India)slit lamp bio microscope. Posterior segment was assessed as follows: both pupils were dilated with 0.5% tropicamide eye drops to view the fundus. Examination of the fundus was then DOI: 10.9790/0853-1605120104 www.iosrjournals.org 2 | Page performed with an indirect ophthalmoscope using a Volk 20 dioptre lens (Indirect Ophthalmoscope, Appasamy associate's-Chennai, India) and direct ophthalmoscope (Neitz halogen ophthalmoscope, Japan). For the purpose of study,we computed ocular findings with mean serum ferritin level, duration and complianceof chelation therapy in thalassemia major patients.
III. Results
Fifty two thalassemia subjects aged 5-14 years and 30 healthy controls aged 5-14 years were evaluated for ocular abnormalities. Among thalassemia major patients 37 subjects (71.1%) were male and 15 subjects (28.8%) were female. The mean age ± standard deviation (SD) of thalassemia patients was 8.40+2.61 SD years. The mean serum ferritin level of thalassemic patients was 2519.96ng/ml, and the mean level of hemoglobin in them was 6.35 ± 0.96 SD g/dl(table no.1) 
Table2 -: Ocular manifestation in thalassemia and control group
In our study among fifty two patients ocular involvements were detected in 31 cases (59.6%) in the form of decreased visual acuity(42.3%) which is a most common finding followed hyperemic disc(34.6%), cup obliteration (23.7%),anterior segment involvement(17.3%) and venous tortuosity (7.6%)in descending order. The prevalence of ocular abnormalities in control group was 19.4%. Odds ratio of patients on Desirox developing ocular manifestations is 3.11. ( with 95 % CI: 0.4233 to 22.8665 ) and p value was 0.2647 . We observed that with increase in duration of chelation therapy there was increase in ocular manifestation but this was not statistically significant(table no. 4)
IV. Discussion
In our study the mean age ± standard deviation (SD) of thalassemia major patients was 8.4+2.61years,this was similar to Adnan Aksoy et al 1 were mean age of study population was 9.31 years. In our study the mean serum ferritin level of thalassemia major patients was 2519.96 ± 1050.78ng/ml, this was similar to Pooja Diwan et al 3 were mean serum ferritin level of the thalassemia children was 2995.2 ng/ml. Frequency of ocular involvement in our study was 59.6%.This was in accordance with studies done by Gaba A et al 4 and Taneja et al 5 who reported ocular involvement in 71.4% and 58% of subjects respectively. We found visual acuity was affected in 42.3% patients ,which was similar to study done by Dalia S.M. et al 6 where decreased visual acuity was seen in 45% and Taneja et al In our study cataract was found in 3.8% of thalassemia major cases. This finding was not consistent with study done by Pooja Diwan et al 3 and Taneja et al 5 where they found cataract in 33% and 44% of thalassemia major cases respectively. This difference was probably due to the reason that other two studies included cases with wide range of age group. In our study Correlation of mean serum Ferritin levels and hyperemic disc was statistically significant (P=0.01).Similar correlation was done by Dalia S.M.et al 6 but no significant correlation was found in their study. Also we found correlation of mean serum Ferritin levels and anterior segment involvement to be statistically significant (P=0.03). Retinal venous tortuosity was observed in 7.6%, this was similar to study done by Pooja Diwan et al 3 and Taneja et al 5 were venous tortuosity was seen in 8% and 11% respectively. In our study we found odds ratio of patients on desirox developing ocular manifestation is 3.1.We observed that with increase in duration of chelation therapy there is increase in ocular manifestations but this was not statistically significant. This was similar to study done by Gosai DK et al 7 in 2014 who reported that duration of deferasirox has no direct relation with ocular anomalies in thalassemia major patients.The increased possibility of ocular manifestations in children with prolonged chelation therapy could be paradox as these children have high duration of disease which can probably explain ocular manifestation.
V. Conclusion
Although all of our thalassemia patients were asymptomatic but large number of ocular abnormalities were detected. Decrease in serum ferritin levels by iron-chelating agents is useful for preventing adverse effects associated with iron overload and regular ophthalmological evaluation to detect early changes in their ocular system due to disease and chelating agentis is recommended, in order to achieve a better life quality for this patient group.
VI. Limitation
The direct effect of chelation therapy on eyes could not ne analayed as all the patients of high age were being on chelation therapy.
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